<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140033</url>
  </required_header>
  <id_info>
    <org_study_id>MFathy</org_study_id>
    <nct_id>NCT03140033</nct_id>
  </id_info>
  <brief_title>Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery</brief_title>
  <official_title>Sublingual Misoprostol Versus Placebo to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized
      Controlled Trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate efficacy and safety of subligual misoprostol in reducing blood
      loss during cesarean section , a randomized double blinded prospective controlled trial
      conducted at Ain Shams maternity hospital . 158 women who fulfilled the inclusion criteria
      enrolled in this study .the patients randomized into two groups one of them will receive
      sublingual misoprostol 400 micrograms ( misotac )and the other will receive placebo( Ranitak
      ),all patients will subjected to history,physical examination,and investigations.preparation
      of patients (preload and antibiotics )according to hospital protocol.All C.S will be perfomed
      using spinal anaesthesia ,pfannenstiel incision of the skin ,open of abdomen in layers ,at
      cord clamping the patients will receive the medication sublingual and 20IU of oxytocin
      intravenous infusion simultaneous by the anesthesiologist,then close in anatomical
      layers.blood loss during C.S will be calculated following placental delivery to the end of
      surgery,and from the end of the operation to 6h after birth.the need for additional
      uterotonics agents,blood transfusion and adverse effects of the study drug will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss during cesarean sections</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Blood loss will be estimated by the anesthesiologist Using soaked towels and suction set after delivery of placenta</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal bleeding</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Calculation of the amount of vaginal bleeding according to the number of soaked pads used after cesarea section for the 1st 6 hrs. Each soaked pad equal 50 cc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure and pulse</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Change in blood pressure and pulse before and after the cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss after 24 hr.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The allowable blood loss (ABL) =[ estimated blood volume ( EBV ) x (intial hematocrit (HI ) - final hematocrit (HF) ] / HI ( initial hematocrit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional uterotonic agent</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Need for additional uterotonic agent e.g oxytocin - methyl ergotamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of patients receiving blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical measures to stop bleeding</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Need for surgical measures to stop bleeding e.g uterine artery ligation , B-lynch sutures or Hysterectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of misoprostol</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Nausea, Vomiting or Diarrhea</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Hemorrhage Postpartum</condition>
  <arm_group>
    <arm_group_label>Misoprostol oral tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranitidine oral tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol Oral Tablet</intervention_name>
    <description>at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually</description>
    <arm_group_label>Misoprostol oral tablets</arm_group_label>
    <other_name>Misotac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine Oral Tablet</intervention_name>
    <description>at cord clamping the patient will recieve ranitidine sublingually</description>
    <arm_group_label>Ranitidine oral tablets</arm_group_label>
    <other_name>Ranitak</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton pregnancies

          -  women booked for elective C.S

          -  full term pregnancies

          -  primi gravida or previous one delivery ( either by spontaneous vaginal delivery or C.S
             )

        Exclusion Criteria:

          -  blood disorders

          -  multiple pregnancy

          -  placenta previa

          -  polyhydramnios

          -  marked maternal anemia

          -  contraindications to prostaglandin e.g history of asthma , allergy to misoprostol

          -  previous 2 or more C.S
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr H YEHIA, MD,MRCOG</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University-Maternity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed H Fathy, M.B.B.Ch</last_name>
    <phone>00201099984100</phone>
    <email>Mohamedfathy31085@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amr YEHIA, MD,MRCOG</last_name>
    <phone>00201227900014</phone>
    <email>am_helmy77@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain shams maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Fathy, M.B.B.Ch</last_name>
      <phone>00201099984100</phone>
      <email>Mohamedfathy31085@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>AMR Helmy, MD.MRCOG</last_name>
      <phone>00201227900014</phone>
      <email>am_helmy77@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Fathy</investigator_full_name>
    <investigator_title>Resident of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

